ユーザーIDをお忘れですか? or パスワードをお忘れですか?

東京ビッグサイト | 有明

2018年11月11日 (日) 午前 9:30 - 2018年11月13日 (火) 午後 5:40

〒135-0063, 東京都江東区有明3-11-1



[V5-S5] Responses Against the Global Threat of Antimicrobial Resistance

Session Chair(s)

Junko  Sato, PhD

Junko Sato, PhD

Associate Executive Director

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

By 2050, the global mortality attributable to antimicrobial resistance (AMR) is estimated to be 10 million, exceeding the mortality attributable to cancer if no actions are taken. In response to this issue, the Japanese government has proposed the “National Action Plan on AMR”. Various measurements against AMR have been considered by industry, government and academia, in areas ranging from drug discovery to the development of new antimicrobials, surveillance and appropriate use of antimicrobials. Focusing on the clinical research and development to tackle AMR, the current issues of the industry, government and academia and future steps for collaboration to efficiently and rapidly develop antimicrobials will be discussed in this session from local and global perspectives.


Wataru  Asakura, PhD

Therapeutic Drug for AMR Infections: from Regulatory Standpoint

Wataru Asakura, PhD

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Office Director, Office of New Drug IV

Mari  Ariyasu

Development Issues of Drugs for AMR Infections

Mari Ariyasu

Shionogi & Co., Ltd., Japan

Head of Project Management 4, Senior Director

Satoshi  Iwata, MD, PhD

Can We Develop Antimicrobials for AMR Infections ? We Can Do It !

Satoshi Iwata, MD, PhD

National Cancer Center Hospital, Japan

Director, Department of Infectious Diseases,